NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
401 trialsNCT04055948 2026-03-30
Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients
Case Comprehensive Cancer Center
Phase NA Completed
NCT06318338 2026-03-27
Virtual Reality to Promote Relaxation Prior to Simulation
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT02362750 2026-03-25
Evaluating Cancer Survivorship Care Models
George Washington University
Completed
NCT03568058 2026-03-24
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Completed
NCT03328663 2026-03-20
Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant
Massachusetts General Hospital
Phase NA Completed
NCT06072833 2026-03-16
Characterizing and Addressing Financial Toxicity in AYAs With Cancer
Columbia University
Phase NA Completed
NCT03833167 2026-03-10
KEYNOTE-630
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05148078 2026-03-02
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT06837090 2026-02-20
SPAINTRK
Grupo Espanol de Tumores Neuroendocrinos
Completed
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT04260529 2026-01-29
CICILIA
Cytovation AS
Phase 1/2 Completed
NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT03824158 2026-01-14
Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial
University of Pittsburgh
Phase NA Completed
NCT06013176 2025-12-29
BEST-PRO
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT03433898 2025-12-19
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
Boehringer Ingelheim
Phase EARLY_PHASE1 Completed
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT03473652 2025-12-15
APPAHOCA
Centre Francois Baclesse
Phase NA Completed
NCT06347731 2025-12-15
Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan)
Varian, a Siemens Healthineers Company
Phase NA Completed
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT05383170 2025-11-28
Catalyst
Cytovation AS
Phase 1/2 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT03656718 2025-11-12
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05847686 2025-11-05
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
University of Washington
Phase 1/2 Completed
NCT03480646 2025-10-29
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT04010240 2025-10-16
NTRK
Institut Bergonié
Completed
NCT02874001 2025-10-06
PO-BADO
Institut Bergonié
Completed
NCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT03972150 2025-10-06
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT03676218 2025-10-03
DATECANelderly
Institut Bergonié
Completed
NCT03694171 2025-10-03
Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Institut Bergonié
Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02674152 2025-10-01
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02689505 2025-10-01
Weekly BI 836880 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02843165 2025-09-30
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
University of California, San Diego
Phase 2 Completed
NCT04614662 2025-09-23
Symptom Screening Linked to Care Pathways
The Hospital for Sick Children
Phase NA Completed
NCT05237206 2025-09-18
Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies
Alloplex Biotherapeutics Inc
Phase 1 Completed
NCT06648161 2025-09-09
Using a Mirror in the Second Stage of Labor: Effects on Duration and Birth Experience
Kocaeli University
Phase NA Completed
NCT02751827 2025-08-24
PreToxE
Institut Bergonié
Completed
NCT04147234 2025-08-19
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT00716417 2025-08-05
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03307629 2025-07-29
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Noxopharm Limited
Phase 1 Completed
NCT01403974 2025-07-25
Phase I Trial of BI 836845 for Various Solid Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT06561217 2025-07-25
Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening
University of Pennsylvania
Completed
NCT04939246 2025-07-17
SMART ONE
Baptist Health South Florida
Phase NA Completed
NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed